News & Resources

Featured Stories

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA Read More

Posted on 11.18.24

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Posted on 5.8.24

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Posted on 1.15.24

WhiteLab Genomics and Siren Biotechnology Announce Strategic Partnership to Accelerate AI-Powered Advancements in Gene Therapy

Posted on 11.1.23

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Posted on 5.17.23

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy

Posted on 5.17.23

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer